Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients

A Clinical Study of Supra-early Post-Surgery Chemotherapy Plus Standard TEMODAL® Regimen Versus Standard TEMODAL® Regimen in the Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme

The primary purpose of the study is to evaluate the efficacy and safety of supra-early post-surgery chemotherapy versus standard TEMODAL® regimen in treatment of patients with newly diagnosed glioblastoma multiforme. The secondary purpose is to assess the efficacy of supra-early post-surgery chemotherapy in release brain edema.

Study Overview

• Status: Unknown
• Conditions: Glioblastoma
• Intervention / Treatment: Drug: standard TEMODAL® chemotherapy; Radiation: Radiotherapy 60Gy; Drug: supra-early TEMODAL® chemotherapy

Detailed Description

Glioblastoma (GBM) is the most common primary malignant brain tumor. Despite great efforts have been devoted to promoting the treatment effect, GBM remains one of the most lethal tumors concurrent with poor prognosis and inevitable recurrence. The standard treatment protocol for GBM includes surgical resection, radiotherapy and temozolomide (TMZ) based chemotherapy. TMZ, an alkylating agent, has been proved to be efficient to control tumor growth after surgery and gradually has been recognized in routine clinical course for GBM. In a pivotal clinical trial published in 2005, GBM patients received concomitant TMZ and radiotherapy followed by 6 periods of adjuvant TMZ chemotherapy had a median survival of 14.6 months and 5-year survival rate of 9.8%, which has been regarded as a landscape in treatment history of GBM. To date, this regimen remains the standard protocol for newly diagnosed GBM patients. However, the optimal timing of initiation of TMZ or radiotherapy remains unclear. Our previous study showed 75mg per square meter of body surface per day (mg/m2/d) of TMZ chemotherapy alone was effective to control post-operative edema caused by tumor cell infiltration in primary GBM patients. The result suggested anti-cancer agents such as TMZ may be a useful regimen to control tumor cell regrowth after operation. Therefore, we conducted this prospective clinical trial to testify the hypothesis that supra-early initiation of TMZ chemotherapy in newly diagnosed GBM patients is effective to control tumor growth after tumor resection and therefore improve patients'clinical outcome.

• Study Type: Observational
• Enrollment (Anticipated): 180

Contacts and Locations

• Study Contact: Name: Song Lin, MD; Phone Number: 8601067096509; Email: linsong2005@126.com
• Study Contact Backup: Name: Chun Zeng, MD; Phone Number: 8613520118570; Email: zengchun79@aliyun.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 100005
      • Recruiting
      • Beijing Tiantan Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 73 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients with prior histological confirmation of newly diagnosed primary glioblastoma multiforme in supratentorial cerebral hemisphere.

Description

Inclusion Criteria:

1. Patients with prior histological confirmation of newly diagnosed primary glioblastoma multiforme in supratentorial cerebral hemisphere.
2. Gross total resection or partial resection (imaging) >70%.
3. Chemo-radiotherapy to be expected from Week 5 (Day 29) after surgery.
4. Age >=18 and <=70 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
6. Life expectancy >=9 months.

7. Laboratory test values must satisfy the following criteria:

   1. absolute neutrophil count >=1.5 x 10^9/L;
   2. platelet count >=100 x 10^9/L;
   3. hemoglobin >=80 g/L;
   4. blood urea nitrogen and creatinine < 1.5 x upper limit of normal value (ULN);
   5. total bilirubin and direct bilirubin < 1.5 x ULN;
   6. alanine aminotransferase and aspartate aminotransferase < 3 x ULN;
   7. alkaline phosphatase < 2 x ULN.
8. Patients must be willing to provide written informed consent.
9. Patients of child-bearing potential (including female subjects and the female partners of male subjects) must use an effective method of contraception.

Exclusion Criteria:

1. Patients without prior histological confirmation of primary glioblastoma multiforme.
2. Patient with previous or current malignancies at other sites.
3. Patient who received chemotherapy, radiotherapy for study indication, or other medications for antitumor indication prior to surgery.
4. Patient with recurrent or multiple malignant glioma (including gliomatosis cerebri).
5. Patient with metastatic lesions at the subtentorial or outside of calvaria.
6. Patient who received chemotherapy or radiotherapy sensitizers for head or neck tumor.
7. Patient who received radiotherapy at head or neck which leads to radiotherapy domain overlapping.
8. Frequent vomiting or medical condition that could interfere with oral medication intake (eg, partial bowel obstruction).
9. Known human immunodeficiency virus (HIV)-positive or acquired immune deficiency syndrome (AIDS)-related illness.
10. Woman who is pregnant or breastfeeding.
11. Patient with a history of hypersensitivity to temozolomide or other analogic alkylating agents.
12. Patient with severe myelosuppression
13. Patient with any other conditions under which investigators think the subject is not suitable for enrolment, such like having known that the subject may not have good compliance.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
TEMODAL® standard therapy regimen; 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.	Drug: standard TEMODAL® chemotherapy; Radiation: Radiotherapy 60Gy
post-surgery supra-early TEMODAL® chemotherapy; Within 24 hours after surgery, Supra-early TEMODAL® Chemotherapy is administered orally at 75mg/m2/day for 28 days for patients pathologically confirmed as GBM. 4 weeks after surgery, patients are administered with radiotherapy that consisted of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily 5 dyas a week over a period of 6 weeks. Concomitant TEMODAL® are administered orally at a daily dose of 75mg/m2 from the first day of radiotherapy until the last day of radiotherapy, but for no longer than 49 days. After a 4-week break, patients were then to receive up to 6 cycles of adjuvant TEMODAL® chemotherapy according to the standard 5-day schedule every 28 days.The dose is 150mg/m2 once daily for cycle 1 and is increase to 200mg/m2 at the beginning of cycle 2, so long as there were no hematologic toxic effects.	Radiation: Radiotherapy 60Gy; Drug: supra-early TEMODAL® chemotherapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
progression free survival	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)		Up to 2 years
Objective Response Rate		Up to 2 years
Treatment-related adverse event	Number of participants with adverse events	Up to 2 years

Collaborators and Investigators

• Sponsor: Beijing Tiantan Hospital
• Investigators: Study Director: Song Lin, MD, Beijing Tiantan Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2015
• Primary Completion (Anticipated): December 1, 2020
• Study Completion (Anticipated): December 1, 2020

Study Registration Dates

• First Submitted: June 26, 2015
• First Submitted That Met QC Criteria: August 9, 2015
• First Posted (Estimate): August 13, 2015

Study Record Updates

• Last Update Posted (Actual): July 11, 2019
• Last Update Submitted That Met QC Criteria: July 9, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: prognosis; supra-early chemotherapy
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Glioblastoma; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Temozolomide
• Other Study ID Numbers: B0008